3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
1324
Neoplasms
982
Carcinoma, Non-Small-Cell Lung
860
Prostatic Neoplasms
724
Colorectal Neoplasms
666
Lung Neoplasms
551
Leukemia, Myeloid, Acute
475
Neoplasm Metastasis
434
Pancreatic Neoplasms
419
Carcinoma, Hepatocellular
407
Multiple Myeloma
396
Ovarian Neoplasms
392
Stomach Neoplasms
379
Recurrence
364
Squamous Cell Carcinoma of Head and Neck
325
Melanoma
294
Brain Neoplasms
287
Uterine Cervical Neoplasms
283
Triple Negative Breast Neoplasms
271
Glioblastoma
264
Head and Neck Neoplasms
263
Precursor Cell Lymphoblastic Leukemia-Lymphoma
254
Endometrial Neoplasms
234
Lymphoma
228
Rectal Neoplasms
222
Esophageal Neoplasms
222
Sarcoma
213
Carcinoma, Renal Cell
203
Colonic Neoplasms
194
Lymphoma, Non-Hodgkin
191
Interventions
sacituzumab govitecan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Interventional
×
Triple Negative Locally Advanced Non-resectable Breast Cancer
×
Clear all
NCT06827613
2025-09-24
START-002
Marengo Therapeutics, Inc.
Phase 1/2
Recruiting
50 enrolled